Between 1995 and 2014, the US has spent $94, 349,576,890 subsidizing corn. That is $94 billion dollars my friends. There are similar trends in soybeans and wheat. But investments in health top out at 1.8 billion for diabetes in 2016. ​There is no similar trend in spending for fresh fruit and vegetables--the sources of nutrition and health we are encouraged to include several times per day.

The American Diabetes Association Applauds Major Funding Increase for Diabetes

The Consolidated Appropriations Act for Fiscal Year 2016 increased discretionary funding for the National Institute of Diabetes and Digestive and Kidney Diseases to $1.818 billion, an increase of over $68 million compared to FY2015. This robust funding will allow the institute to expand promising research toward improved treatments and move us closer to a cure for diabetes. 

The legislation also provided significantly increased funding of $170.129 million for the Division of Diabetes Translation at the Centers for Disease Control and Prevention (CDC). The $30 million funding increase will help the agency better carry out its mission to reduce the preventable burden of diabetes. 

Last, the spending bill doubled funding for the CDC’s National Diabetes Prevention Program to $20 million. This increased funding will allow more individuals with prediabetes to access evidence-based community prevention programs that can help lower their risk for developing type 2 diabetes.

The Expanded Learning Model for Systems (TELMS), offers a framework for designing, implementing, and evaluating learning solutions that move both HCPs and patients through a series of learning stages to enable them to adopt evidence-based behaviors informed by quality and performance indicators, and which will help CE stakeholders to demonstrate how such changes lead to improvements in care coordination and quality of care.

Although the FDA has traditionally focused on the safety and efficacy of drugs relative to placebo, there are abundant good reasons for the agency to push industry and other study sponsors to use active controls in type 2 diabetes studies. The major clinical role of the new drugs is as alternative treatments, not as therapies for patients who otherwise would not be treated with drugs.

I highlight Novo-Nordisk only because Victoza tops the list in physician renumeration. It also tops a few other lists if you investigate quarterly trends in FDA Adverse Event Database (FAERS) data reported by Druginformer.

How a national food policy could save millions of American lives-- Mark Bittman, Michael Pollan, Ricardo Salvador and Olivier De Schutter

The food system and the diet it’s created have caused incalculable damage to the health of our people and our land, water and air. If a foreign power were to do such harm, we’d regard it as a threat to national security, if not an act of war, and the government would formulate a comprehensive plan and marshal resources to combat it. (The administration even named an Ebola czar to respond to a disease that threatens few Americans.) ​So when hundreds of thousands of annual deaths are preventable — as the deaths from the chronic diseases linked to the modern American way of eating surely are — preventing those needless deaths is a national priority.

​

I am not a statistician. I am a consumer of statistics courses from undergraduate, graduate, and post-graduate studies. I possess a theoretical grasp of numeracy that still allows a never-ending pipeline of questions and scientific inquiry. I am unable to think of one post-graduate course that hasn't become out-dated. A dusty PhD in an obscure biological subspecialty may gain entry but my expertise in population genetics would be a relic--if I wan't continually learning... I have mentioned the fire-hose of data and information--let's try to find a story in the numbers.

Cardiovascular Mortality in Patients With Type 2 Diabetes and Recent Acute Coronary Syndromes From the EXAMINE Trial

​New Orleans (June 11, 2016) – Health-related quality of life (HRQOL) is an important area of investigation that has gained increasing recognition and is a critical element of diabetes research, treatment and care, according to experts at the Symposium, “Beyond A1C—Why Quality of Life Matters,” presented on June 11, 2016, during the American Diabetes Association’s 76th Scientific Sessions®, June 10-14, 2016, at the Ernest N. Morial Convention Center in New Orleans. 
 
Treating People, Not Numbers: Assessing Health-Related Quality of Life (HRQOL)
Diabetes treatment and care often focuses on measurable goals, such as maintaining target blood glucose levels. “It’s important, however, for healthcare providers and investigators to also take into account patients’ quality of life (QOL), which is more difficult to measure, yet can greatly impact outcomes,” said Lawrence Fisher, PhD, Professor Emeritus, Department of Family and Community Medicine at the University of California, San Francisco, in his presentation, “Quality of Life, Issues of Conceptualization and Measurement.”
 
“Using blood glucose numbers or improved glycemic control as outcome measures is too limited,” continued Fisher. “Patient quality of life can be a better predictor of mortality and morbidity than some biologic measures.”
 
It is critical that a comprehensive HRQOL assessment is incorporated into the structure of trials—to measure at baseline and at intervals that correspond and complement the study’s treatment protocol. “Patients provide a perspective that investigators can often miss. Early and continuous patient feedback is crucial for us to develop and employ the most effective strategies that can improve QOL and biologic outcome measures.”
 
All outcomes will not be achieved at the same pace, noted Fisher. For example, changes in glycemic control, behavior and quality of life are unlikely to occur simultaneously. “The introduction of a continuous glucose monitor might lead in the short term to improvements in glycemic control. However, the initial data overload can be very distressing for patients, so changes in quality of life might not become apparent until far later in comparison to changes in blood glucose levels.”
 
”We must consider patient experience feedback and quality of life data to be as important as biologic outcomes,” Fisher concluded.
 
Questionnaires Measure Quality of Life for People with Type 1 Diabetes and Their Caregivers
“Questionnaires for people with type 1 diabetes and their caregivers should soon provide a better means of measuring quality of life across the course of their lives, from early childhood through late adulthood,” said Marisa E. Hilliard, PhD, Assistant Professor of Pediatrics, Baylor College of Medicine, Texas Children’s Hospital, in her presentation, “Developing a Measure of Diabetes Health-related Quality of Life Across the Lifespan—Preliminary Qualitative Findings.”
 
Hilliard and her team are currently conducting a mixed-methods study—interviewing people with type 1 diabetes and their caregivers (parents and partners) in order to better understand the quality of life issues they experience at different points in life. 
The interviews have informed the research team’s development of new patient-reported outcome measures of diabetes-related quality of life, which will be validated across the United States this year. The new measures will be able to inform and improve patient-centered research and care. 
 
“People with diabetes are more than their glycemic control data,” she said. “The day-to-day experiences of living with and managing type 1 diabetes need to be better understood and addressed in clinical research and practice. Developed from the personal stories of people with diabetes and their family members, we hope the new patient-reported outcome measures we are developing will advance our ability to prioritize quality of life in clinical research and care. It is equally as important as glycemic control to the overall health and well-being of people with diabetes and their families.”
 
“Several themes have emerged from an analysis of the interviews conducted to-date,” said Hilliard, such as “worries about life with diabetes, challenges of managing diabetes care expenses, and the importance of supportive communication among family members and health care providers. We have learned quite a bit from how people told their stories and what they emphasized. For example, we were pleased to hear so many of our participants talking about the ’silver linings‘ of life with diabetes, their strategies to manage the burdens of diabetes, and their gratitude for the pace of technology advances and for the strong support of the diabetes community.”
 
 “By creating a suite of QOL measures that extend across the lifespan and can be used with both people with diabetes and their caregivers, we anticipate the measures will allow for consistent, longitudinal and outcomes research that can more accurately evaluate the impact of treatments and therapies on everyday life,” she said. “This will help bring to market new intervention approaches that meet more of the needs of people with and impacted by diabetes.”
 
Look AHEAD: Modest Weight Loss Yields Long-Term Quality of Life Benefits
Modest weight loss can significantly improve quality of life for middle-aged and older adults with type 2 diabetes, yielding benefits such as greater ease in performing daily tasks, reduced pain, greater mobility and a better state of mind, according to a review of findings from the Look AHEAD study. The analysis, “Quality of Life Findings from the Look AHEAD Study,” will be presented by Gareth R. Dutton, PhD, Associate Professor of Medicine, University of Alabama Division of Preventive Medicine.
 
The National Institute of Health-funded Look AHEAD (Action for Health in Diabetes) trial () was designed to test whether intensive lifestyle intervention (ILI)—healthy eating and increased physical activity—for weight loss could reduce the occurrence of cardiovascular disease, stroke and cardiovascular-related deaths in obese and overweight patients with type 2 diabetes. While the intervention yielded no reduction in the rate of cardiovascular events, it did achieve other benefits including improved quality of life. The trial included 5,145 adults from 16 clinical centers across the country, ages 45 to 75, with type 2 diabetes and a body mass index (BMI) greater than 25. Patient accrual was terminated after 11 years, when conclusions indicated the study’s primary outcome of reducing cardiovascular events would not be achieved. At that time, median follow-up for patients was 9.6 years. 
 
Study participants were randomly assigned to ILI (n=2,570) or standard of care diabetes support and education (the control group, n=2,575). The ILI group achieved significantly greater weight loss than the control group, with a mean weight loss of 6 percent at the end of the study, compared to 3.5 percent in the control group. Patients in the ILI group experienced significant QOL improvements, such as improved physical function and mobility (defined as the ability to get around and perform daily functions without pain or other limitations).
 
In addition, the ILI group experienced a 48 percent lower risk of loss of mobility, with 12.3 percent (308 of 2,514 patients) of those in the ILI group experiencing severe mobility-related disability after one year, compared to 18.9 percent (474 of 2,502 patients) in the control group. After four years, 20.6 percent (n=517) of the ILI group experienced severe mobility-related disability, compared to 26.2 percent (n=656) of those in the control group. Participants in the ILI group were also 15 percent less likely to experience elevated symptoms of depression eight years following the initiation of treatment.
 
Both groups experienced decreased physical function over time. The ILI group, however, demonstrated an initial significant improvement in functioning during the first year of treatment and continued to report better physical function during the following 8 years of the trial. This suggests that modest weight loss may help to mitigate deteriorations in physical function and QOL that typically occur with aging.  
 
“It is notable that some of the quality of life benefits—physical functioning and depressive symptoms—were still present nearly a decade after individuals began treatment for weight loss,” said Dutton. “These long-term benefits were also preserved even when there was some degree of weight regain.”  
 
“The results highlight the need to consider a variety of benefits for patients with type 2 diabetes who are able to lose a modest amount of weight,” said Dutton. “Many of the outcomes we measured, including physical functioning, mobility and depressive symptoms, are very important to patients who are understandably interested in maximizing their quality of life and maintaining their independence for as long as possible.”
 
Dutton’s review includes data previously published in Diabetes Care, the New England Journal of Medicine, and the Archives of Internal Medicine.-- mkirkwood@diabetes.org

Recommending gastric bypass as a national solution for our diabetes epidemic is bad medicine and bad economics.-- Mark Hyman, MD

Surrogate outcomes are defined as a laboratory measurement or a physical sign used as a substitute for a clinically meaningful endpoint that measures directly how a patient feels, functions or survives, and that is expected to predict the effect of the therapy.

Surrogates are often biomarkers such as hemoglobin A1C [HbA1c], blood pressure, lipid levels, etc. Surrogate outcomes are used in clinical trials for reasons of efficiency and practicality; they can be measured with fewer patients, less invasiveness and a shorter observation period.

Where surrogate outcomes have validated links with final endpoints, their use can greatly facilitate clinical research. However, in the absence of validated links, there can be uncertainty about patient benefit; and even where the epidemiologic basis is sound, long-term safety and other unanticipated issues may predominate.

For example, while blood pressure is conclusively linked to cardiovascular morbidity and mortality, antihypertensive drugs do not necessarily reduce morbidity or mortality as expected.-- Surrogate outcomes: experiences at the Common Drug Review

2016 Banting Medal for Scientific Achievement